EYECARE: Coronavirus BRIEFING: Crisis Response Tactics FDA Panel Strongly Backs Protein-Based Novavax COVID Vaccine By Staff Wednesday, June 8, 2022 7:58 AM A federal advisory panel strongly supported a bid for Novavax to win U.S. emergency authorization for its COVID-19 vaccine.The Vaccines and Related Biological Products Advisory Committee of the FDA voted near unanimously Tuesday in favor of Novavax's two-dose COVID-19 vaccine for those 18 or older—despite some concerns over rare events of myocarditis, (inflammation of the heart muscle), and pericarditis, (inflammation of tissue surrounding the heart).The tally was 21 "yes" votes, without any "no" votes, but one abstention from a panelist who then offered a largely positive take on this vaccine. Head over to WebMD to read the full story.